Clinical trials: SARS CoV 2 Infection
Covid19
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.
- Trial name
- NCT04676867
- Testing
- Dalcetrapib
- Where
- Canada
- Volunteers
- 227 people
- Sponsor
- DalCor Pharmaceuticals
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
Covid19
Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients
Randomized, double-blind, placebo-controlled pilot study to evalaute viral load in saliva of COVID19+ patients using quantitative PCR, before and after use of active or placebo rinses
- Trial name
- NCT04563689
- Testing
- CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)
- Where
- Colombia
- Volunteers
- 23 people
- Sponsor
- Dentaid SL
COVID-19
Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)
In late December 2019, a new coronavirus strain emerged in China causing coronavirus disease 2019 (COVID-19). Since then, COVID-19 has become a global pandemic outbreak being declared a "public health emergency of international…
- Trial name
- CONDITION (NCT04389658)
- Where
- Spain
- Volunteers
- 1,526 people, healthy volunteers welcome
- Sponsor
- Igenomix
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19 Patients
To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)
This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients.
- Trial name
- NCT04541485
- Testing
- DWRX2003
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Covid19
COVIDIG (COVID-19 Hyper-ImmunoGlobulin)
The objective of this study is to evaluate the efficacy and safety of 5131A for hospitalized patients of COVID-19.
- Trial name
- NCT04555148
- Testing
- GC5131
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Green Cross Corporation
Covid19, COVID-19 Pneumonia
imPulse™ Una Infrasound-to-ultrasound E-stethoscope
This study generates robust, uniform clinical data across emerging COVID-19 strains to train ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for digital diagnostic feature synthesis of…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT04941209
- Testing
- imPulse™ Una infrasound-to-ultrasound e-stethoscope, (PPA >95%) FDA EUA RT-PCR, HR-CT-scan
- Where
- 3 sites in Democratic Republic of the Congo, India and 1 more
- Volunteers
- 702 people
- Sponsor
- Level 42 AI, Inc.
Covid19
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19
The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019.
- Trial name
- NCT05035576
- Testing
- OPN-019
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Optinose US Inc.
COVID-19, Asymptomatic COVID-19
A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test
To determine the accuracy of Proof Diagnostics COVID-19 Test in the intended, symptomatic and suspected/at-risk asymptomatic population and point-of-care use as compared to a standard molecular comparator, Quidel Lyra SARS-CoV-2…
- Trial name
- NCT05331976
- Testing
- Proof Lab Test System
- Where
- 3 sites in United States
- Volunteers
- 276 people
- Sponsor
- Proof Diagnostics
SARS-CoV-2 Infection( COVID-19 )
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
- Trial name
- NCT04888949
- Testing
- Mesenchymal stem cell
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
COVID-19, SARS-CoV2
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04468958
- Testing
- SAB-185, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
COVID-19
Immunogenicity of an Inactivated COVID-19 Vaccine
This study is an open phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.
- Trial name
- NCT05198336
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design to evaluate the immunogenicity and safety profile of LYB001 in healthy adults aged 18 years and older.
- Trial name
- NCT05137444
- Testing
- LYB001
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
Covid19
Niclosamide in COVID-19
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
- Trial name
- NCT04542434
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
COVID-19 Pneumonia, COVID-19 Respiratory Infection
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05212532
- Testing
- EOM613
- Where
- 4 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- EOM Pharmaceuticals
COVID-19 Pandemic
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05158855
- Testing
- Bacillus subtilis spore extract
- Where
- Macau
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.